



Brief Communication

Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency



Graeme R. Frank^a, Joyce Fox^b, Ninfa Candela^c, Zorica Jovanovic^d, Elena Bochukova^d, Jeremiah Levine^c, Peter R. Papenhausen^e, Stephen O'Rahilly^d, I. Sadaf Farooqi^{d,*}

^a Cohen Children's Medical Center, Division of Pediatric Endocrinology, New Hyde Park, NY 11042, USA

^b Cohen Children's Medical Center, Division of Human Genetics, New Hyde Park, NY 11042, USA

^c Cohen Children's Medical Center, Division of Pediatric Gastroenterology, New Hyde Park, NY 11042, USA

^d University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK

^e National Director, Cytogenetics, Laboratory Corporation of America, Research Triangle Park, NC 27709, USA

ARTICLE INFO

Article history:

Received 8 February 2013

Received in revised form 3 April 2013

Accepted 3 April 2013

Available online 17 April 2013

Keywords:

Obesity

Prohormones

ABSTRACT

Non-synonymous mutations affecting both alleles of *PCSK1* (proprotein convertase 1/3) are associated with obesity and impaired prohormone processing. We report a proband who was compound heterozygous for a maternally inherited frameshift mutation and a paternally inherited 474kb deletion that encompasses *PCSK1*, representing a novel genetic mechanism underlying this phenotype. Although pro-vasopressin is not a known physiological substrate of *PCSK1*, the development of central diabetes insipidus in this proband suggests that *PCSK1* deficiency can be associated with impaired osmoregulation.

© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.

1. Introduction

Proprotein convertases (PCs) are a family of serine endoproteases that cleave inactive pro-peptides into biologically active peptides [1]. Two family members, Proprotein Convertase Subtilisin/Kexin types 1 and 2 (*PCSK1* and *PCSK2*) are selectively expressed in neuroendocrine tissues where they cleave a broad but specific set of prohormones including pro-opiomelanocortin (POMC), prothyrotrophin releasing hormone (TRH), proinsulin, proglucagon, and progonadotrophin releasing hormone (GnRH) [2–9]. Congenital deficiency of *PCSK1* has previously been reported in three unrelated probands with severe hyperproinsulinemia, malabsorptive diarrhea, hypogonadotropic hypogonadism, partial central defects in the adrenal and thyroid axes and severe obesity [10–12]. At least some of these phenotypes can be explained by the known or suggested involvement of *PCSK1* in the processing of proinsulin, proopiomelanocortin, proglucagon, proGnRH and proTRH [1]. We describe the fourth patient with *PCSK1* deficiency whose phenotype, in addition to the above, included central diabetes insipidus.

2. Research design and methods

Direct nucleotide sequencing of the *PCSK1* gene was carried out as previously reported [10]. SNP microarray analysis was performed

using the Affymetrix 6.0 platform using 500 ng of total genomic DNA. Data was analyzed using Affymetrix Genotyping Console Browser v.3.01. Multiplex Ligation-independent Probe Amplification (MLPA) probes in the *PCSK1* gene region (chr5:95751875–95774445) were designed following MRC-Holland (The Netherlands) recommendations (<http://www.mlpa.com/>) and sequences are available upon request. MLPA Hybridization, ligation and PCR were carried out using 200 ng of genomic DNA and the SALSA-MLPA kit (MRC-Holland, The Netherlands), according to the manufacturer's instructions. The MLPA PCR products (1 µl) were mixed with 0.5 µl GeneScan™-500 ROX™ size standard (Applied Biosystems, UK) and 10 µl of HiDi formamide (Applied Biosystems, UK) and separated on an ABI 3130 genetic analyzer (Applied Biosystems, UK) and electrophoresis data extracted using GeneMapper software v4.0 (Applied Biosystems, UK).

3. Results

The male proband weighed 3.8 kg at birth. Diarrhea began at three days of life and persisted despite oral feeding with multiple formula changes. Endoscopy and flexible sigmoidoscopy revealed a grossly normal esophagus, stomach and duodenum, and scattered ulcers in the sigmoid colon. Pathology reported eosinophils present in the duodenum, stomach and colon and eosinophilic cryptitis in the colon consistent with “allergic colitis”. Due to continued diarrhea and failure to thrive, parenteral nutrition together with continuous nasogastric feeds of an amino-acid based formula was instituted at 2 months of age. Watery diarrhea, however, continued. At 3 months the patient was admitted for sepsis associated with his intravenous catheter. Within 2 h of central line

* Corresponding author.

E-mail address: isf20@cam.ac.uk (I.S. Farooqi).

removal, his blood glucose fell to 33 mg/dl, with a low serum cortisol of 11.60 µg/dl (normal > 18 µg/dl) and a normal growth hormone (13.8 ng/ml). Thyroid function was consistent with central hypothyroidism (TSH 1.60 µU/ml) with free thyroxine levels of 0.78 ng/dl (normal 0.9–1.8 ng/dl) and a low testosterone (28 ng/dl) and micropenis noted on clinical examination. In view of these findings, he was diagnosed with partial hypopituitarism and started on hydrocortisone and thyroxine replacement therapy. Monthly testosterone injections for 3 months resulted in the normalization of his penile size. Persistent polydipsia and polyuria were noted in the third year of life. Following restriction of fluid overnight, his serum Na was 145 mEq/l, Cl 107 mEq/l and osmolality was 304 mOsm/kg (urine specific gravity was 1.010 and osmolality 386 mOsm/kg), confirming the diagnosis of diabetes insipidus. He was started on oral desmopressin which led to a marked improvement in symptoms and electrolyte abnormalities.

From 12 months, rapid weight gain began despite an apparent average caloric intake of ~70 kcal/kg/day. Some solid foods were introduced for the first time at about 14 months, and this resulted in improved stool consistency and less frequent diarrhea. By 24 months old, the child was grossly obese (Fig. 1A). The amino-acid based formula was discontinued at 3 years of age.

In view of the combination of chronic diarrhea, rapid weight gain and selective hypopituitarism, the possibility of PCSK1 deficiency was entertained. A nonfasting plasma insulin was low (0.2 µU/ml) but proinsulin was >200 µU/ml. Direct nucleotide sequencing of *PCSK1* revealed an apparently homozygous single base pair deletion which results in a frameshift after Pro 341, with the introduction of 91 abnormal amino acids terminating in a premature stop codon (W342GfsX92). The mutation is located within a region that encodes the catalytic domain and thus would be expected to abolish PCSK1 function. The proband's mother was found to be heterozygous for the same mutation. However, no *PCSK1* mutation was found in his father. SNP microarray analysis revealed a 474kb interstitial deletion of 5q15-q15 (95669703–96143955) which contains three genes, *PCSK1*, calpastatin and endoplasmic reticulum aminopeptidase 1. This deletion was confirmed by Multiplex Ligation-independent Probe Amplification (MLPA) and was also found in the patient's father (Figs. 1B and C). Thus, the patient had inherited a large deletion that encompassed the *PCSK1* gene and also a frameshift mutation within the gene resulting in the loss of both alleles and the phenotype of *PCSK1* deficiency. Common heterozygous variants in *PCSK1* have been associated with late-onset obesity [13]. However, both parents of this proband were of normal weight and had no evidence of intestinal or endocrine abnormalities. While these findings do not preclude a more subtle effect of some *PCSK1* variants on body weight, the loss of both *PCSK1* alleles appears to be necessary for the complete phenotype.

4. Discussion

We describe the fourth patient with *PCSK1* deficiency due to the combination of a maternally inherited frameshift mutation leading to a premature stop and a paternal deletion on chromosome 5 encompassing *PCSK1* and two adjacent genes. This patient differs significantly from the three previous cases all of which involved homozygosity or compound heterozygosity for missense or splice site mutations [10–12]. In this case one allele was deleted and the other disrupted by a 91 amino acid insertion followed by a premature stop codon occurring within the catalytic domain. While some residual *PCSK1* enzymatic activity could conceivably have persisted in the three previously reported cases it seems highly likely that this patient represents the null phenotype of *PCSK1*.

The development of central diabetes insipidus in our patient suggests that *PCSK1* may be involved in the full functioning or central

sensing of osmolality in humans. Whether this is due to the failure of vasopressin processing or to some other malfunction of osmoreception or vasopressin production or release is unknown. Vasopressin is synthesized in hypothalamic neurons expressing both *PCSK1* and *PCSK2* [5]. In mice, both *PCSK1* and *PCSK2* are involved in the processing of pro-vasopressin to vasopressin, suggesting that a degree of redundancy may exist in vivo [6,14,15]. In summary we report the fourth patient with *PCSK1* deficiency. The finding of diabetes insipidus in this patient, and clinical features suggestive of this diagnosis in one patient previously reported by us [12], suggest that this potentially clinically significant and treatable abnormality should be sought in future patients presenting with this syndrome.

Conflict of interest

None of the authors have a conflict of interest.

Acknowledgments

ISF and SOR were supported by the Wellcome Trust, the MRC Centre for Obesity and Related Disorders and the UK NIHR Cambridge Biomedical Research Centre.




Fig. 1. A. Growth chart of proband demonstrating marked failure to thrive over first 2 months; stabilization of weight gain from 2 months (with introduction of parenteral nutrition and an amino acid based formula) and excessive weight gain from 1 year. B. Family tree with chromatograms. Wildtype (Wt); deletion (del). C. MLPA confirmation of 474kb deletion of 5q15-q15 (95669703–96143955). Patient's MLPA traces are in red overlaid on the control MLPA traces in black. MLPA probes for genes in the region of interest are detailed below. Two of the MLPA probes are positioned within the *PCSK1* gene and appear to be deleted in the patient (arrows), and two are on either side of the deleted region on chromosome 5q15 (distal and proximal probes), and they are identical to the normal control.




Fig. 1 (continued).

References

- [1] N.G. Seidah, The proprotein convertases, 20 years later, *Methods Mol. Biol.* 768 (2011) 23–57.
- [2] P. Schaner, R.B. Todd, N.G. Seidah, E.A. Nillni, Processing of prothyrotropin-releasing hormone by the family of prohormone convertases, *J. Biol. Chem.* 272 (1997) 19958–19968.
- [3] D.Q. Barge-Schaapveld, S.M. Maas, A. Polstra, L.C. Knegt, R.C. Hennekam, The atypical 16p11.2 deletion: a not so atypical microdeletion syndrome? *Am. J. Med. Genet. A* 155A (2011) 1066–1072.
- [4] S. Benjannet, N. Rondeau, R. Day, M. Chretien, N.G. Seidah, PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues, *Proc. Natl. Acad. Sci. U. S. A.* 88 (1991) 3564–3568.
- [5] W. Dong, B. Seidel, M. Marcinkiewicz, M. Chretien, N.G. Seidah, R. Day, Cellular localization of the prohormone convertases in the hypothalamic paraventricular and supraoptic nuclei: selective regulation of PC1 in corticotrophin-releasing hormone parvocellular neurons mediated by glucocorticoids, *J. Neurosci.* 17 (1997) 563–575.
- [6] B.A. Gabreels, D.F. Swaab, D.P. de Kleijn, N.G. Seidah, J.W. Van de Loo, W.J. Van de Ven, G.J. Martens, F.W. van Leeuwen, Attenuation of the polypeptide 7B2, prohormone convertase PC2, and vasopressin in the hypothalamus of some Prader–Willi patients: indications for a processing defect, *J. Clin. Endocrinol. Metab.* 83 (1998) 591–599.
- [7] N.S. Rangaraju, R.B. Harris, GAP-releasing enzyme is a member of the pro-hormone convertase family of precursor protein processing enzymes, *Life Sci.* 52 (1993) 147–153.
- [8] Y. Rouille, S. Martin, D.F. Steiner, Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide, *J. Biol. Chem.* 270 (1995) 26488–26496.
- [9] S.P. Smekens, A.G. Montag, G. Thomas, C. Albiges-Rizo, R. Carroll, M. Benig, L.A. Phillips, S. Martin, S. Ohagi, P. Gardner, et al., Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3, *Proc. Natl. Acad. Sci. U. S. A.* 89 (1992) 8822–8826.
- [10] R.S. Jackson, J.W. Creemers, S. Ohagi, M.L. Raffin-Sanson, L. Sanders, C.T. Montague, J.C. Hutton, S. O'Rahilly, Obesity and impaired prohormone processing associated with

- mutations in the human prohormone convertase 1 gene [see comments], *Nat. Genet.* 16 (1997) 303–306.
- [11] R.S. Jackson, J.W. Creemers, I.S. Farooqi, M.L. Raffin-Sanson, A. Varro, G.J. Dockray, J.J. Holst, P.L. Brubaker, P. Corvol, K.S. Polonsky, et al., Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency, *J. Clin. Invest.* 112 (2003) 1550–1560.
- [12] I.S. Farooqi, K. Volders, R. Stanhope, R. Heuschkel, A. White, E. Lank, J. Keogh, S. O'Rahilly, J.W. Creemers, Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3, *J. Clin. Endocrinol. Metab.* 92 (2007) 3369–3373.
- [13] M. Benzinou, J.W. Creemers, H. Choquet, S. Lobbens, C. Dina, E. Durand, A. Guerardel, P. Boutin, B. Jouret, B. Heude, et al., Common nonsynonymous variants in PCSK1 confer risk of obesity, *Nat. Genet.* 40 (2008) 943–945.
- [14] A. Hardiman, T.C. Friedman, W.C. Grunwald Jr., M. Furuta, Z. Zhu, D.F. Steiner, D.R. Cool, Endocrinomic profile of neurointermediate lobe pituitary prohormone processing in PC1/3- and PC2-Null mice using SELDI-TOF mass spectrometry, *J. Mol. Endocrinol.* 34 (2005) 739–751.
- [15] J.H. Wardman, X. Zhang, S. Gagnon, L.M. Castro, X. Zhu, D.F. Steiner, R. Day, L.D. Fricker, Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics, *J. Neurochem.* 114 (2010) 215–225.